Approval Background and Drug Information

Ingenus Pharmaceuticals, a U.S.-based pharmaceutical company, has received approval from the U.S. Food and Drug Administration (FDA) for its generic version of Leucovorin Calcium tablets (5mg, 10mg, 15mg, 25mg) (ANDA 211132). Leucovorin Calcium is a folic acid derivative that is essential in the rescue therapy for patients undergoing high-dose Methotrexate chemotherapy, preventing bone marrow and gastrointestinal toxicity. This approval is expected to contribute to stabilizing the supply chain of this essential supportive cancer treatment and reducing the financial burden on patients.

Clinical Efficacy and Pharmacological Mechanism

Leucovorin is actively reduced in the body and converted into active forms of folic acid, such as 5-Methyltetrahydrofolate. When the chemotherapeutic agent Methotrexate inhibits dihydrofolate reductase (DHFR), blocking folic acid metabolism, Leucovorin bypasses this step and helps restore DNA and RNA synthesis in normal cells. Clinical studies have shown that administering Leucovorin within 24 hours after high-dose Methotrexate administration significantly reduces acute toxicity, including severe bone marrow suppression and mucositis.

Market Competition and Positioning Analysis

The global Leucovorin Calcium market is estimated at approximately $250 million in 2023, and is expected to grow at a steady rate of over 4% annually due to the continued use of FOLFOX and FOLFIRI, which are standard treatments for colorectal cancer. This market is highly competitive, dominated by major generic companies such as Teva, Fresenius Kabi, and Pfizer/Hospira. Ingenus is expected to pursue a strategy of diversifying tablet formulations and optimizing its manufacturing processes to secure a price advantage over existing competitors.

Regulatory History and Market Entry Prospects

This ANDA was finally approved on July 30, 2020, and has been launched and prescribed in the U.S. market since then. As a generic drug, it was approved after undergoing bioequivalence testing without a separate advisory committee (AdComm) review. In the U.S., generic drugs are generally automatically included in the reimbursement system, making market entry relatively easy. However, securing long-term contracts with hospital purchasing organizations (GPOs) is expected to be a key factor in expanding market share in the early stages.